BNT162b2 mRNA加强针后血管免疫母细胞性T细胞淋巴瘤快速进展：一例报告
Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report.
作者信息
Goldman Serge, Bron Dominique, Tousseyn Thomas, Vierasu Irina, Dewispelaere Laurent, Heimann Pierre, Cogan Elie, Goldman Michel
机构信息
Department of Nuclear Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Department of Hematology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
出版信息
Front Med (Lausanne). 2021 Nov 25;8:798095. doi: 10.3389/fmed.2021.798095. eCollection 2021.
Since nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type. Herein, we report and discuss unexpected rapid progression of lymphomatous lesions after administration of a BNT162b2 mRNA vaccine booster in a man recently diagnosed with AITL.
由于核苷修饰的mRNA疫苗会强烈激活滤泡辅助性T细胞，因此探究已获批的SARS-CoV-2 mRNA疫苗对影响该细胞类型的肿瘤可能产生的影响具有重要意义。在此，我们报告并讨论了一名近期诊断为血管免疫母细胞性T细胞淋巴瘤（AITL）的男性在接种BNT162b2 mRNA疫苗加强针后淋巴瘤病变意外快速进展的情况。
Zotero 插件